Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChromaDex Corporation - Common Stock (NQ: CDXC )

7.900 +0.020 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Earnings Preview: ChromaDex
Via Benzinga
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
From ChromaDex Corpor
Via Business Wire
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
From ChromaDex Corporation
Via Business Wire
This Analyst Cuts ChromaDex's Price Target On Revised Growth Trajectory
Via Benzinga
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
From ChromaDex Corporation
Via Business Wire
A Letter from the ChromaDex Chief Executive Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
From ChromaDex Corporation
Via Business Wire
ChromaDex Named Brianna Gerber Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
From ChromaDex Corporation
Via Business Wire
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
From ChromaDex Corporation
Via Business Wire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
From ChromaDex Corporation
Via Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
From ChromaDex Corporation
Via Business Wire
$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones jumped by more than 750 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. 
Via Benzinga
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
From ChromaDex Corporation
Via Business Wire
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
From ChromaDex Corporation
Via Business Wire
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
From ChromaDex Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
  
Via Benzinga
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
From ChromaDex Corporation
Via Business Wire
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
From ChromaDex Corporation
Via Business Wire
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022
  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.